Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Gilead Sciences logo
Gilead SciencesGILD
$4.75B+17.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$297K-19.1%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue-
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$550.99M+780%
Enterprise value$258.93M+450%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029
Line itemAS OF / JUNE 30,2026AS OF / DECEMBER 31,2025
Property and equipment, net5,6716,618
Operating lease right-of-use assets9,23610,525
Financing lease right-of-use asset180212
Other long-term assets809458
Total assets$368,633$130,940
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$1,386$355

Item 1. Financial Statements

FAQ

What is Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets?
Artiva Biotherapeutics, Inc. (ARTV) reported deferred tax assets and other non-current assets of $809K in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets increased by 2028.9% year-over-year, from $38K to $809K.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets has grown at a 8.1% compound annual growth rate (CAGR), from $392K to $458K.
What does deferred tax assets and other non-current assets mean?
Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.

Ask your AI about Artiva Biotherapeutics, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude